Hepatitis B Virus Treatment: 2017 Newcomers
|
|
- Cody Morris
- 5 years ago
- Views:
Transcription
1 Clinical Hepatology Update Clinical Hepatology Update Hepatitis B Virus Treatment: 2017 Newcomers Sang Hoon Ahn Department of Internal Medicine, Institute of Gastroenterology, Yonsei Liver Center Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea Introduction Chronic hepatitis B virus (HBV) infection is an important public health problem and a leading cause of liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC) with substantial disease burden. 30% of liver cirrhosis and roughly 53% of HCC is attributed to chronic hepatitis B, especially in Asia and the Western Pacific region.[1] Despite effective HBV vaccine has been recommended from the 1992s, treatments for chronic hepatitis B is still crucial because of low vaccination coverage in many countries and low percentage of individuals with no or low development of antibody. To date, the main goal in HBV therapy has been suppression of HBV replication, because it is associated with reduced rates of liver complications, improving quality of life, and greater long-term survival [2]. During the last three decades, several antiviral drugs have been developed. Two main classes of antiviral drugs for chronic hepatitis B is currently available; two formulation of interferon (IFN)-conventional and pegylated IFN as immunomodulatory agents, and nucleos(t)ide analogues (NAs) including lamivudine, telbivudine, adefovir, entecavir and tenofovir. IFN has multiple mechanisms of action including antiviral, antiproliferative and immunomodulatory effects, and better chances for off-treatment virological response and loss of HBV surface antigen (HBsAg). However, its use is limited by side effects such as flu-like symptoms and exacerbation of underlying immune conditions, and is contraindicated in advanced cirrhosis cases. The effectiveness and safety of NAs are supported by recent systematic review and meta-analyses, suppress viral replication by inhibiting the reverse transcriptase activity of HBV polymerase, and thus prevent viral replication. But NAs do not directly target covalently closed circular DNA (cccdna), which is the template for all viral RNAs, so HBV is often reactivated after discontinuing NAs. Despite many years of antiviral treatment, the low percentage of treated patients achieve HBsAg loss (only 5-8% in 3 years) [3, 4], and lifelong treatment is often needed to prevent viral rebound. Various clinical trials have been conducted on agents that terminate the HBV life cycle in hepatocytes, including inhibitors of HBV-DNA polymerase, virus entry, core assembly, and secretion of hepatitis B surface antigen (HBsAg). [Figure 1][5] Newly antiviral agents are currently in development, including immunomodulatory agents enhancing host immunity and direct virus targeting agents blocking each step of HBV life cycles such as entry inhibitor, inhibitors of nucleocapsid assemblies, new polymerase inhibitors, RNA interference agents, inhibitors of HBsAg release, and agents that target cccdna. These new agents are arranged in [Table 1] and [Table 2]. This review highlights newly investigated therapeutic compounds and approaches in clinical trials and selected preclinical researches
2 The Liver Week 2017 Figure 1. Hepatitis B virus life cycle along with inhibitors targeting the various stages of the hepatitis B virus lifecycle (Adapted from Grimm et al 2011 [5]) Following attachment of virus to the receptors, cell entry and release of nucleocapsid, nuclear import of virus to nucleus, transcription and translation leads to the synthesis of covalently closed circular DNA (cccdna), envelopment of nucleocapsid within endoplasmic reticulum, formation of multivesicular bodies and finally secretion of subviral and virion particles. Moreover red bar lines shows the inhibitors targeting various stages of the virus life cycle such as: entry inhibitors, inhibition of cccdna formation, and inhibition of assembly, polymerase inhibition and genetic editing and immunomodulation targeting the cell surface receptors. ISG: Immune serum globulin. Table 1. DIRECT ACTING ANTIVIRALS: Targets the virus and interferes in the HBV replication process Entry Inhibitors: Interferes with HBV getting into liver cells Myrcludex B Entry inhibitor Phase 2 cccdna inhibitors: cccdna degredation, silencing, and elimination ZFNs Block transcription of cccdna, inhibit production, repression of Preclinical TALENs cccdna transcriptional activity, and gene editing to mutate Preclinical CRISPR-Cas9 cccdna Preclinical CCC-0975 directly block the conversion of rcdna to cccdna Preclinical CCC-0346 directly block the conversion of rcdna to cccdna Preclinical LTβR agonist upregulates APOBEC3B Preclinical Capsid Inhibitors: Interferes with the viral DNA protein shield Morphothiadin (GLS4) Capsid inhibitor Phase 2 NVR Capsid inhibitor Phase 2 AIC 649 Capsid inhibitor Phase 1 JNJ Capsid Inhibitor Phase 1 ABI-H0731 Core Protein Allosteric Modifiers (CpAMs) Phase 1 AB-423 Core Protein Allosteric Modifiers (CpAMs) Phase June 22-24, 2017 Grand Hyatt Incheon, Korea
3 Clinical Hepatology Update HBsAg Inhibitors: Interferes with production of HBV surface antigen (sag) Rep 2139 sag inhibitor Phase 2 Rep 2165 sag inhibitor Phase 2 RO (RG7834) sag inhibitor Phase 1 GC1102 Recombinant Hepatitis B Human Immunoglobulin Phase 1 Antisense Molecules: Binds to the viral mrna to prevent it from turning into viral protein IONIS-HBVRx (GSK ) Viral protein inhibitor Phase 1 IONIS-HBVLRx (GSK ) Viral protein inhibitor Phase 1 Silencing RNA s (sirnas): Interferes and destroys viral RNA ARB-1467 RNAi gene silencer (1.0) Phase 2 ARB-1740 RNAi gene silencer (2.0) Phase 2 ALN-HBV RNAi gene silencer Preclinical Hepbarna (BB-HB-331) RNAi gene silencer Preclinical Lunar-HBV RNAi gene silencer Preclinical ARO-HBV RNAi gene silencer Preclinical TDF Pro Drugs: A modified tenofovir drug that can get into liver cells more easily Vemlidy Approved in USA, Prodrug of tenofovir (TAF or tenofovir alafenamide) Nov Besifovir Acyclic nucleotide phosphonate Pending Approval only in Korea TXL (CMX 157) Prodrug of tenofovir Phase 2 AGC-2009 Prodrug of tenofovir Phase 1 MIV-210 Prodrug of tenofovir Phase 1 Table 2. INDIRECT ACTING ANTIVIRALS: Targets the human immune system to attack the HBV virus Innate Immune Defense Pathway: Compounds that activate the innate immune system GS 9620 TLR-7 agonist Phase 2 RO (RG7795, ANA773) TLR-7 agonist Phase 2 SB9200 RIG -1 and NOD2 agonist Phase 2 Therapeutic Vaccines: Vaccine technology used to stimulate the immune system as a treatment INO-1800 Therapeutic vaccine Phase 1 HB-110 Therapeutic vaccine Phase 1 TG1050 Therapeutic vaccine Phase 1 HepTcell Therapeutic vaccine Phase 1 TomegaVax HBV Therapeutic vaccine Preclinical Entry inhibitor The hepatocyte-specific cellular sodium-taurocholate co-transporting polypeptide (NTCP) has been identified as a functional receptor for HBV and hepatitis D virus. Myrcludex B is a synthetic lipopepetide that competes with the viral envelope pre-s1 motif for NTCP binding thereby blocking HBV entry. [6] This prevents the infection of naïve hepatocytes, so could be used to prevent post-exposure infection, such as after liver transplantation in recipients with HBV, and neonates of HBV positive mothers. Entry inhibitor could be less effective in pre-existing infection, but could increase clearance of previously infected hepatocytes by providing proper time window when combinated with NAs, interferon, or other innovative therapies. Myrcludex B showed >1log IU/mL reduction in serum HBV DNA among 75% patients in phase 2a clinical study, but there was no noteworthy change in HBsAg concentrations. Higher dosage was associated with a clinically insignificant hyperbilirubinemia. [7] 293
4 The Liver Week 2017 cccdna degredation, silencing, and elimination After binding NTCP receptor, HBV enters hepatocytes through two ways: fusion with the viral envelope at the plasma membrane, or endocytosis, uncoating, and delivery of nucleocapsids to the nucleus where relaxed circular DNA (rcdna) is converted to the highly stable cccdna. This cccdna acts as a template for multiple viral mrna transcripts synthesized via host RNA polymerase II. Nucleos(t)ide analogue-based treatments can block the replication and formation of new cccdna, but they have negligible effect on existing cccdna which is key to viral persistence and reactivation after cessation of therapy. Engineered site-specific nucleases can inhibit HBV replication, and three most commonly used engineered DNA-binding proteins targeting cccdna are below: Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the RNA-guided clustered regulatory interspaced short palindromic repeats (CRISPR) and CRISPR associated (Cas) protein endonucleases. These DNA-binding proteins induce site-specific cleavage of DNA by transcriptional block, repression of transcriptional activity, or gene editing to mutate cccdna.[8] In addition, two structurally related disubstituted sulphonamides, called CCC-0975 and CCC-0346, were recently identified through a cell-based screening strategy. These compounds directly block the conversion of rcdna to cccdna, result in inhibition of cccdna formation.[9] These preclinical materials have shown effective inhibition of HBV DNA replication in vitro studies. Other recent studies showed that activation of apolipoprotein B mrna editing enzyme, catalytic polypeptide-like proteins (APOBEC3A and APOBEC3B) in HBV infected cells interacts with the HBV core and translocate to the nucleus, inducing noncytotoxic cccdna degradation. As immune modulators, interferon alpha upregulates APOBEC3A, and lymphotoxin-β receptor (LTβR) agonist upregulates APOBEC3B.[10] In-vivo and in-vitro stimulation of LTβR led to reduction in HBV DNA and cccdna concentration with persistent effects after cessation of therapy and no hepatotoxic effects. But long-term data are needed for LTβR agonists. RNA interference and gene silencing, targeting expression of HBV genes Small interfering RNAs (RNAi) can disturb gene expression by binding and inactivating host or viral mrna. HBV-specific small interfering RNA showed to reduce expression of viral proteins in vitro, and ARC-520, a liver-tropic cholesterol-conjugated small interfering RNA, showed effective knockdown of HBV RNA, proteins, and HBV DNA levels in phase 2a randomized controlled study. [11] Gene silencing can be achieved by introducing a short antisense oligonucleotide complementary to an RNA target, that has shown a dose-dependent reduction of HBsAg concentrations in vivo, and further trials in heterogenous populations with durable endpoints are ongoing. Nucleocapsid assembly inhibitors The HBV core proteins are translated from the pregenomic RNA and self-assemble into nucleocapsids, encapsidating pregenomic RNA and HBV polymerase, and allowing genome replication to proceed. Thus, HBV replication and cccdna replenishment can be prevented by inhibition of nucleocapsid assembly, deestablishing the nucleocapsid and blocking RNA packaging to produce empty capsids without genetic information. Phenylpropenamide derivatives (AT-61 and AT130), and sulfamoylbenzamide derivatives prevent the encapsidation of pregenomic RNA into nucleocapsid, and heteroaryldihydropyrimidines (Bay , GLS4) may induce inappropriate assembly. NVR is another assembly inhibitor that has shown reduction of HBV viral load by alone or combination with pegylated interferons.[12] These occur prior to viral DNA synthesis, so effective against both wild-type and nucleos(t)ide analogues-resistant HBV. Bay and GLS4 are in the phase 1 for clinical trials, and NVR is in the phase 2a. 294 June 22-24, 2017 Grand Hyatt Incheon, Korea
5 Clinical Hepatology Update HBsAg release inhibitor HBsAg was seen to suppress cytokine production and induce T-cell tolerance and exhaustion, resulting in suppression of host immune responses. Thus, control of HBsAg secretion can be a strategy to restore HBV-specific T-cell-mediated immune control. REP 2139-ca is an amphipathic DNA polymer, blocks HBsAg secretion from infected hepatocytes in patients with chronic HBV infection, which resulted in the recovery of innate immunity and cytotoxic T cell response in a phase I clinical study.[13] Polymerase inhibitors As described, development of drug resistance is the major limitation of long-term NAs therapy, and new potent polymerase inhibitors are being developed to dodge emergence of drug resistance. Tenofovir alafenamide (TAF, or known as GS-7340) is second-generation prodrug of tenofovir. It is designed to resist rapid metabolism in the plasma, and efficiently delivered to infected hepatocytes and metabolized to active form (tenofovir diphosphate). TAF showed higher intracellular active metabolite form levels as well as lower plasma tenofovir concentrations, and has no renal transporter-dependent cytotoxicity (organic anion transporters, OAT1 and OAT3) which may reduce the risk of renal function impairment, comparing with TDF. Recent randomized phase 3 studies showed that virological response of TAF using group at week 48 was non-inferior to TDF, and TAF treatment had significant improvements in both renal and bone safety than TDF, [14] and approved in November 2016 in USA as Vemlidy. Besifovir is an acyclic nucleotide phosphonate with rapid intracellular phosphorylation to inhibit HBV replication. Its efficacy of viral suppression and HBeAg seroconversion was no different to entecavir therapy in a multicenter randomized trial. [15] Other compounds in phase 2 clinical trials include CMX-157, AGX-1009, and MIV-210 (lagociclovir valactate) which have shown favorable reduction in HBV DNA and cccdna concentrations in phase 1 studies. Immunomodulatory agents Immunomodulators can change the host response to HBV, improving immune control or leading to viral eradication. Novel approaches to host targeting agents include immune-enhancement with the toll-like receptor (TLR) agonists, therapeutic vaccines, cytokines, and immune checkpoint inhibitors such as PD-1 blockers (as known with remarkable tumor responses in various oncologic clinical studies). TLRs are important pathogen recognition receptors that stimulate innate and adaptive immune responses. Several studies reported that HBV downregulates TLR in mice modules resulting in suppression of anti-viral activity, and the expression of TLR in hepatocytes reduces HBV viral products. GS-9620 was developed as a selective oral TLR7 agonist that could induce peripheral interferon-stimulated gene 15 production and suppression of HBV DNA in chimpanzee modules and recent phase 1b study, but unfortunately could not show the superior efficacy in recent phase 2 study. Other agents including RG7795 (ANA773) as a TLR7 agonist and ARB-1598 as a TLR9 agonist are ongoing in phase 1 studies. Therapeutic vaccines theologically can activate the adaptive immune system to neutralize HBV with upregulation of CD4 and CD8 T-cell responses, and provide an effective immune response. GS-4774 and ABX-203 was developed as recombinant therapeutic vaccines with HBV antigenicity that stimulate HBV-specific CD8(+) T-cell, but showed little efficacy in people volunteered or incomplete primary endpoint in each phase 2 and phase 2b/3 studies. NCT , the combination of therapeutic vaccine HB-110 (known novel HBV DNA vaccine that showed increased in vivo immunological potency) and entecavir, complete phase 1 trial and is enrolling patients in phase 2 trials. Other adenovirus-based therapeutic vaccine such as TG1050 is also in phase 1 trials. Induction of immune checkpoint inhibitors such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte angigen 295
6 The Liver Week (CTLA-4) can be increased in chronic HBeAg-positive patients with high viral load. [16] PD-1 blockade can increase CD8(+) T cell proliferation and enhanced HBcAg-specific interferon-gamma production in intrahepatic lymphocytes in vitro and in vivo, leading to increased HBV-specific T-cell cytotoxicity and antiviral immunity. If possible, development of more selective and protective PD-1 blockades and therapeutic plans such as combining with nucleos(t)ide analogues therapy can lead to archive protective immunity against HBV with a subsequent cure of HBV. Conclusion Pegylated interferon and NAs such as tenofovir and entecavir are present and mainstream treatment for chronic hepatitis B. However, currently available antiviral agents do not provide complete cure, and the development of cirrhosis, HCC, liver-related complication and mortality are still remaining a major threat. Potential treatment strategies and new agents are emerging to cure HBV, and combinations of current and new anti-hbv agents may increase the rate of HBsAg seroclearance. Although most agents are under early phase development, more safe agents such as TAF, and other novel agents targeting various steps in the HBV lifecycle and host immune responses showed a possibility of functional cure in many preclinical research and clinical trials. With these efforts, a cure for chronic HBV and global HBV control can be hopefully expected. References 1. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, : a systematic analysis for the Global Burden of Disease Study Lancet. 2015;386: Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011; 5: Volz T, Allweiss L, MBarek MB, et al. The entry inhibitor Myrcludex-B effi ciently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: Bogomolov P, Voronkova N, Allweiss L, et al. A proofof-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. Hepatology 2014; 60: 1279A-80A. 8. Maepa MB, Roelofse I, Ely A, Arbuthnot P. Progress and prospects of ant-hbv gene therapy development. Int J Mol Sci 2015; 16: Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012; 56: Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccdna. Science 2014; 343: Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013; 21: Yuen M-F, et al. Abstract LB06. Presented at: International Liver Congress; April 13-17, 2016; Barcelona. 13. Mahtab MA, Bazinet M, Vaillant A. REP 9 AC: a potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection. Hepatology 2011; 54(Suppl 1): 478A. 14. Chan HLY, Fung S, Seto WK, et al. A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg positive chronic HBV: week 48 efficacy and safety results. J Hepatol 2016; 64:S Yuen MF, Ahn SH, Lee KS, et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol 2015; 62: Peng G, Luo B, Li J, et al. Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients. J Clin Immunol 2011; 31: June 22-24, 2017 Grand Hyatt Incheon, Korea
Hepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationNew Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD
New Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD Department of Medicine. The University of Hong Kong, Queen Mary Hospital, Hong Kong OVERVIEW Emerging Drugs against HBV Direct-acting antiviral
More informationHBV Treatment Pipeline: Prospects for a Cure. Marion Peters, MD UCSF San Francisco, CA
HBV Treatment Pipeline: Prospects for a Cure Marion Peters, MD UCSF San Francisco, CA HBV Control Inflammatory: normalize serum ALT, biopsy Virologic: decrease HBV DNA Immune: seroconversion HBeAg to anti-hbe
More informationHBV Novel Therapies Maria Buti MD, PhD
HBV Novel Therapies Maria Buti MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital CONFLICT OF INTEREST I have financial relationships to disclose within the past 12 months relevant
More informationWhy do we need new HBV treatment and what is our definition for cure?
Why do we need new HBV treatment and what is our definition for cure? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University
More information23 ε Γηεκερίδα Ιογελώλ Ηπαηηηίδωλ Β θαη C «Ση. Χαηδεγηάλλες» 30 θαη 31 Ιαλοσαρίοσ 2016
23 ε Γηεκερίδα Ιογελώλ Ηπαηηηίδωλ Β θαη C «Ση. Χαηδεγηάλλες» 30 θαη 31 Ιαλοσαρίοσ 2016 Λεηηοσργηθή θαη Ιοιογηθή Ιαζε ηες Χρολίας Ηπαηίηηδας Β: Παρόλ θαη Μέιιολ Σηέθαλος Χαηδεγηάλλες Οκόηηκος Καζεγεηής
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationNew HBV Treatment Options on the Horizon
New HBV Treatment Options on the Horizon Harry L.A. Janssen Director of Liver Clinic Toronto Western & General Hospitals University of Toronto, Canada Erasmus University Medical Center Rotterdam, The Netherlands
More informationUnderstanding new medicines to treat chronic hepatitis B: toward a cure. October 26, 2016
Understanding new medicines to treat chronic hepatitis B: toward a cure October 26, 2016 Define an HBV cure Functionally (practical): Sustained, off drug response (loss of viremia and antigenemia Clinically:
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationThe HBV pipeline and what the SIG can offer
The HBV pipeline and what the SIG can offer Current treatments and definition of cure Where can we get to with current therapies? Special interest group possibilities Where are we headed with HBV cure
More informationHBV Entry inhibitors, HBV cccdna inhibitors & others
HBV Entry inhibitors, HBV cccdna inhibitors & others 홍영미 부산대학교의과대학양산부산대병원내과 Young Mi Hong Department of Internal Medicine, College of Medicine Pusan National University, Liver center, Pusan National University
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationHBV Cure Overview of Viral and Immune Targets
HBV Cure Overview of Viral and Immune Targets Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada October
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationHBV Cure Definition and New Drugs in Development
HBV Cure Definition and New Drugs in Development Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement
Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer
More informationReview article: novel therapies for hepatitis B virus cure advances and perspectives
Alimentary Pharmacology and Therapeutics Review article: novel therapies for hepatitis B virus cure advances and perspectives C.-L. Lin*, & J.-H. Kao,,, ** *Department of Gastroenterology, Renai branch,
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationImmune Modulation for HBV Cure
Immune Modulation for HBV Cure Ulrike Protzer Institute of Virology echnische Universität München / Helmholtz Zentrum München echnische Universität München How can hepatitis B be cured? 1. killing of infected
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationUnderstanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development
Understanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationRichard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-
More informationTargeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING
More informationManagement of HBV infection between Specialist and General Practitioners
13 October 2016 Management of HBV infection between Specialist and General Practitioners Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationRNA Interference: A New Tool in the Toolbox for Treatment of HBV. Discovery On Target Senior Director, Research 25 September 2017
RNA Interference: A New Tool in the Toolbox for Treatment of HBV Amy Lee Discovery On Target Senior Director, Research 25 September 2017 Arbutus Biopharma Boston, MA NASDAQ: ABUS www.arbutusbio.com Chronic
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationIs There a Best Direct Acting Antiviral Agent for HBV?
Is There a Best Direct Acting Antiviral Agent for HBV? Fabien Zoulim Hepatology Department, Hospices Civils de Lyon INSERM U1052, Cancer Research Center of Lyon Lyon University, France What targets for
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationThis is a free sample of content from The Hepatitis B and Delta Viruses. Click here for more information on how to buy the book.
Index A Acute liver failure (ALF), viral hepatitis, 7 Adalimab, hepatitis B management in immunosuppression patients, 279 Alemtuzumab, hepatitis B management in immunosuppression patients, 280 ALF. See
More informationDisease Pathways and Mechanisms of Potential Drug Targets
Disease Pathways and Mechanisms of Potential Drug Targets Marc G. Ghany, M.D., M.HSc.,* and Timothy M. Block, Ph.D. Hepatitis B virus (HBV) is a small, partially double-stranded DNA virus that can cause
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationNuevos tratamientos para la hepatitis B y Delta.
Nuevos tratamientos para la hepatitis B y Delta. Dra. María Buti. Servicio de Hepatología. Hospital Universitario Vall d Hebron. Barcelona. hat does HBV cure mean? Functional Cure Clinical resolution sustained
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationNovel Bispecific Antibodies for Treating Hepatitis B Virus Infection. Dr. Felix Bohne
Novel Bispecific Antibodies for Treating Hepatitis B Virus Infection Dr. Felix Bohne Munich, 11.05.2015 Consequences of Hepatitis B Virus 2 Global prevalence of Hepatitis B (percentage of population per
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationSERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca
SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca Louis Jansen 1,2, Andrew Vaillant 3, Karel van Dort 1, Femke Stelma 1,2, Neeltje
More informationResponse-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon
Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More informationSpontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report
Hara et al. Surgical Case Reports (2016) 2:118 DOI 10.1186/s40792-016-0246-2 CASE REPORT Open Access Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationCHRONIC HEPATITIS B VIRUS Prospects for Cure
VIRAL HEPATITIS and CO-INFECTION with HIV Bucharest, Romania, 6-7 October, 2016 CHRONIC HEPATITIS B VIRUS Prospects for Cure Patrick T. F. Kennedy Reader in Hepatology & Consultant Hepatologist Blizard
More informationNew therapeutic perspectives in HBV: when to stop NAs
Liver International ISSN 1478-3223 REVIEW ARTICLE New therapeutic perspectives in HBV: when to stop NAs Cristina Perez-Cameo, Monica Pons and Rafael Esteban Liver Unit, Department of Internal Medicine,
More informationHBV Forum pre-easl 2018
HBV Roadmap Update from Recent and EASL Presentations HBV Forum pre-easl 2018 Robert G Gish MD Adjunct Professor Stanford University Medical Director HB Foundation See robertgish.com Disclosures Introduction
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationby author Novel approaches towards HBV cure
Jörg Petersen Liver Unit IFI Institute at Asklepios Klinik St. Georg University of Hamburg Germany email: petersen@ifi-medizin.de Novel approaches towards HBV cure New horizons in Hepatitis B,D, and E,
More informationRNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R.
RNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R. October 20, 2017 Safe Harbor Statement This presentation contains forward-looking
More information6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami
Grant/Research Support: AbbVie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen, Discovery Life Sciences, Beckman Coulter, Inc., Siemens Corporation, MedMira Inc., Conatus Eugene R.
More informationEndpoints and New Targets for Curing Hepatitis B
Endpoints and New Targets for Curing Hepatitis B Professor Stephen Locarnini WHO Regional Reference Laboratory for Hepatitis B Victorian Infectious Diseases Reference Laboratory, Doherty Institute Melbourne,
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationNew Approaches to Hepatitis B Therapy
ew Approaches to Hepatitis B Therapy YSGE Course 2016 Ira M. Jacobson, M.D. Chairman, Department of Medicine Mount Sinai Beth Israel Professor of Medicine Icahn School of Medicine at Mount Sinai Themes
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationHepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review
Hepatitis virus immunity Mar 9, 2005 Rehermann and Nascimbeni review Crispe review HBV & HCV infection outcomes Both viruses cause immune-mediated active and chronic hepatitis HBV Vertical transmission
More informationMutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
More informationHBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD
HBV/HCV Eradication Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationThe Evolution of sirna Therapeutics Targeting HBV at Arrowhead Pharmaceuticals. Sept 25, 2018
The Evolution of sirna Therapeutics Targeting HBV at Arrowhead Pharmaceuticals Sept 25, 2018 Disclosures I am an employee and shareholder in Arrowhead Pharmaceuticals, Inc. Safe Harbor Statement This presentation
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationMedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article
HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders Nina Nikolova, Deian Jelev, Krassimir Antonov, Lyudmila Mateva, Zahariy Krastev. University Hospital St. Ivan Rilski Sofia, Clinic
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationTreatment Op+ons for Chronic Hepa++s B. Judith Feinberg, MD Project ECHO Jan. 19, 2017
Treatment Op+ons for Chronic Hepa++s B Judith Feinberg, MD Project ECHO Jan. 19, 2017 Treatment of Chronic Hepatitis B can be prevented by vaccinacon (part of infant series since 1992-3) goal of drug therapy
More informationHepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma
Editorial Hepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma Kazunori Kawaguchi, Masao Honda, Shuichi Kaneko Department of Gastroenterology, Kanazawa University
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationALN-HBV. Laura Sepp-Lorenzino November 11, Alnylam Pharmaceuticals, Inc.
ALN-HBV Laura Sepp-Lorenzino November 11, 2016 2016 Alnylam Pharmaceuticals, Inc. 1 N-Acetyl Galactosamine (GalNAc) sirna Conjugates Subcutaneous Investigational RNAi Therapeutics 5 -sense 5 -AS ASGPR
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationRNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationIntrinsic cellular defenses against virus infection
Intrinsic cellular defenses against virus infection Detection of virus infection Host cell response to virus infection Interferons: structure and synthesis Induction of antiviral activity Viral defenses
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationViral hepatitis. The word hepatitis means inflammation of the liver. There are five main types of viral hepatitis: A, B, C, D, E
Viral hepatitis The word hepatitis means inflammation of the liver There are five main types of viral hepatitis: A, B, C, D, E Hepatitis A and E are typically caused by ingestion of contaminated food or
More informationNew (Virological) Tools for Testing and Monitoring Hepatitis B and C
New (Virological) Tools for Testing and Monitoring Hepatitis B and C Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious Diseases Reference Laboratory, Doherty
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More information